Similar benefits of 5-years simvastatin therapy among high cardiovascular risk patients, independently of baseline C-reactive protein concentration – The Heart Protection Study Discussion

Main Article Content

Barbara Wizner

Abstract

The article presents the vascular effects of 5-years statin therapy according to the different baseline concentrations of C-reactive protein and LDL cholesterol. To the Heart Protection Study, 20 536 patients aged 40–80 years at high cardiovascular risk, hospitalized in United Kingdom between 1994–1997 were involved.

Downloads

Download data is not yet available.

Article Details

How to Cite
Wizner , B. (2011). Similar benefits of 5-years simvastatin therapy among high cardiovascular risk patients, independently of baseline C-reactive protein concentration – The Heart Protection Study. Cardiology in Practice, 5(1), 35-37. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1615
Section
Articles

References

1. Hueghes S.: Statin benefits similar irrespective of CRP level: New HPS data [online: http://www.theheart.org/article/1177999.do] (z dn. 07.03.2011).
2. Després J.P.: CRP: Star trekking the galaxy of risk markers. Lancet 2011, 377: 441-442 [DOI:10.1016/S0140-6736(10)62316-1].
3. Choudhry N.K., Patrick A.R., Glynn R.J., Avorn J.: The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J. Am. Coll. Cardiol. 2011, 57: 784-791.